Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer crawled date : 2022 - 11 - 07 save search
Personalis Presents Data from New Platform Features at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Published: 2022-11-07 (Crawled : 23:00) - biospace.com/
PSNL | $1.2 -3.23% -3.33% 360K
|
Health Technology
|
| O: 0.79%
H: 2.95%
C: -9.02%
immunotherapy meeting cancer platform
Navidea Biopharmaceuticals Announces Details of Presentation at Upcoming Society for Immunotherapy of Cancer Annual Meeting
Published: 2022-11-07 (Crawled : 22:00) - biospace.com/
NAVB | $0.0342 50.69% 23K
|
Health Technology
|
| O: 7.53%
H: 0.88%
C: 0.0%
immunotherapy meeting presentation cancer
Data From Incyte’s Oncology Portfolio to Be Presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Published: 2022-11-07 (Crawled : 18:00) - biospace.com/
INCY | $52.74 -0.9% -0.91% 2.5M
|
Health Technology
|
| O: 0.25%
H: 0.46%
C: -2.05%
immunotherapy meeting cancer
Therapeutic Solutions International Spin-Off Res Nova Bio Collaborates with Veltmeyer MD Inc. to Provide Breast Cancer Patients Access to Novel Cancer Immunotherapy
Published: 2022-11-07 (Crawled : 18:00) - biospace.com/
TSOI | $0.0008 0.0% 5.5M
|
Manufacturing
|
| O: 0.0%
H: 3.96%
C: 0.99%
solutions immunotherapy breast cancer international
Adicet Bio Showcases Preclinical Data for Four New Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Published: 2022-11-07 (Crawled : 13:20) - biospace.com/
ACET | $2.26 3.2% 3.1% 760K
|
Health Technology
|
| O: 0.73%
H: 7.78%
C: 6.44%
preclinical immunotherapy meeting cancer
Oncolytics Biotech® Reports Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting
Published: 2022-11-07 (Crawled : 13:20) - prnewswire.com
ONCY | $1.045 -3.24% -3.35% 180K
|
Health Technology
|
| O: 9.52%
H: 10.87%
C: 8.7%
biotech meeting response results cancer study pancreatic phase 1
NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting
Published: 2022-11-07 (Crawled : 13:20) - globenewswire.com
NXTC | $1.51 -7.93% -8.61% 120K
|
Health Technology
|
| O: -1.52%
H: 2.31%
C: -12.31%
nc762 immunotherapy meeting nc410 trial cancer
F-star Therapeutics Announces Publication of Phase 1 Dose-Escalation Trial of FS118 in Patients with Advanced Cancer and PD-L1 Resistance in Clinical Cancer Research
Published: 2022-11-07 (Crawled : 13:00) - globenewswire.com
FSTX | $7.12 0.0% 0
|
Health Technology
|
| O: 0.88%
H: 0.0%
C: -5.44%
fs118 research trial therapeutics cancer publication phase 1
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.